Open Studies
Suvorexant to reduce symptoms of nicotine use: A double-blind, placebo-controlled study
(NCT04234997)
The purpose of this study is to see how well a drug called suvorexant works at treating symptoms related to cigarette smoking. This medication has been approved by the Food and Drug Administration (FDA) for the treatment of insomnia (trouble sleeping). Based on previous research, we believe this medication may relieve some of the negative effects that nicotine can have on the body.
Contact: 713-500-DRUG (3784)
The effects of abstinence on EEG power and attention in cocaine use disorder
The purpose of this study is to compare the brain processes involved in attention of current cocaine users and those who have been abstinent for at least one month. These brain responses are expected to help us understand how the brain recovers after no longer using cocaine and to identify attention problems that can be addressed in future treatments.
Contact: 713-500-DRUG (3784)
Neuroimaging and Brain Cell Structure and Function in Substance Abuse (InVitro and In Vivo Evidence of Neurotoxicity in Substance Abuse)
The purpose of this study is to determine the relationship between brain structure (as measured by brain imaging) and genetic/cellular processes in new brain cells (generated from skin cells taken) in (a) people who use cocaine and (b) people who are similar in age, race, and gender but do no use cocaine (“healthy control” participating)
Contact: 713-500-DRUG (3784)